{"id":"https://openalex.org/W1596584892","doi":"https://doi.org/10.1111/j.1742-1241.2011.02812.x","title":"Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study","display_name":"Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study","alternate_titles":[],"publication_year":2011,"publication_date":"2011-10-07","ids":{"openalex":"https://openalex.org/W1596584892","doi":"https://doi.org/10.1111/j.1742-1241.2011.02812.x","mag":"1596584892","pmid":"https://pubmed.ncbi.nlm.nih.gov/21977965"},"language":"en","primary_location":{"id":"doi:10.1111/j.1742-1241.2011.02812.x","doi":"https://doi.org/10.1111/j.1742-1241.2011.02812.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1742-1241.2011.02812.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2011.02812.x","source":{"id":"https://openalex.org/S22344484","display_name":"International Journal of Clinical Practice","issn_l":"1368-5031","issn":["1368-5031","1742-1241"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Clinical Practice","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1596584892"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2011.02812.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045007278","display_name":"Michal P. Nowicki","orcid":"https://orcid.org/0000-0002-0823-5440","observed_orcids":["https://orcid.org/0000-0002-0823-5440"]},"institutions":[{"id":"https://openalex.org/I4210122071","display_name":"Medical University of Lodz","ror":"https://ror.org/02t4ekc95","country_code":"PL","type":"education","lineage":["https://openalex.org/I4210122071"]}],"countries":["PL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Nowicki","raw_affiliation_strings":["Medical University, \u0141\u00f3d\u017a, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical University, \u0141\u00f3d\u017a, Poland","institution_ids":["https://openalex.org/I4210122071"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047980902","display_name":"Ivan Rychl\u00edk","orcid":"https://orcid.org/0000-0002-4245-5949","observed_orcids":["https://orcid.org/0000-0002-4245-5949"]},"institutions":[{"id":"https://openalex.org/I21250087","display_name":"Charles University","ror":"https://ror.org/024d6js02","country_code":"CZ","type":"education","lineage":["https://openalex.org/I21250087"]}],"countries":["CZ"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"I. Rychlik","raw_affiliation_strings":["Charles University Third School of Medicine, Prague, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Charles University Third School of Medicine, Prague, Czech Republic","institution_ids":["https://openalex.org/I21250087"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110143117","display_name":"Hermann G. Haller","orcid":"https://orcid.org/0000-0002-8361-6446","observed_orcids":["https://orcid.org/0000-0002-8361-6446","https://orcid.org/0009-0000-5740-838X"]},"institutions":[{"id":"https://openalex.org/I34809795","display_name":"Medizinische Hochschule Hannover","ror":"https://ror.org/00f2yqf98","country_code":"DE","type":"education","lineage":["https://openalex.org/I34809795"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. Haller","raw_affiliation_strings":["Medizinische Hochschule Hannover, Hannover, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medizinische Hochschule Hannover, Hannover, Germany","institution_ids":["https://openalex.org/I34809795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011320591","display_name":"Mark Warren","orcid":"https://orcid.org/0000-0001-6693-9860","observed_orcids":["https://orcid.org/0000-0001-6693-9860"]},"institutions":[{"id":"https://openalex.org/I4210159269","display_name":"Physicians East","ror":"https://ror.org/053prtv35","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210159269"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Warren","raw_affiliation_strings":["Physician\u2019s East, P.A., Greenville, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Physician\u2019s East, P.A., Greenville, NC, USA","institution_ids":["https://openalex.org/I4210159269"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060489809","display_name":"Lisa J. Suchower","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L. Suchower","raw_affiliation_strings":["AstraZeneca LP, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca LP, Wilmington, DE, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007149007","display_name":"Ingrid A. M. Gause\u2010Nilsson","orcid":"https://orcid.org/0000-0002-3758-8237","observed_orcids":["https://orcid.org/0000-0002-3758-8237"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"I. Gause-Nilsson","raw_affiliation_strings":["AstraZeneca R&D, Mo\u0308lndal, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D, Mo\u0308lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111466547","display_name":"K-M. Sch\u00fctzer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K-M. Sch\u00fctzer","raw_affiliation_strings":["AstraZeneca R&D, Mo\u0308lndal, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca R&D, Mo\u0308lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2350,"currency":"USD","value_usd":2350},"apc_paid":null,"fwci":11.0868,"has_fulltext":true,"cited_by_count":136,"citation_normalized_percentile":{"value":0.99055683,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"65","issue":"12","first_page":"1230","last_page":"1239"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/saxagliptin","display_name":"saxagliptin","score":1.0},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9660000205039978},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":1.0},{"id":"https://openalex.org/keywords/renal-dysfunction","display_name":"renal dysfunction","score":0.9869999885559082},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.984000027179718},{"id":"https://openalex.org/keywords/hemodialysis","display_name":"hemodialysis","score":0.9800000190734863},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9679999947547913},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.9350000023841858},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.9330000281333923},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4560000002384186},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.6539999842643738}],"concepts":[{"id":"https://openalex.org/C2780282729","wikidata":"https://www.wikidata.org/wiki/Q3121121","display_name":"Saxagliptin","level":5,"score":0.9864320755004883},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9359220266342163},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6826640367507935},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.6722352504730225},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6430127620697021},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5897043347358704},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5270286202430725},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.433419793844223},{"id":"https://openalex.org/C3019040382","wikidata":"https://www.wikidata.org/wiki/Q476921","display_name":"End stage renal disease","level":3,"score":0.4103230834007263},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3516658544540405},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3480742573738098},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3191802501678467},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.28864002227783203},{"id":"https://openalex.org/C2778063415","wikidata":"https://www.wikidata.org/wiki/Q391744","display_name":"Hemodialysis","level":2,"score":0.22479495406150818},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2071460783481598},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000704","descriptor_name":"Analysis of Variance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004151","descriptor_name":"Dipeptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004151","descriptor_name":"Dipeptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005215","descriptor_name":"Fasting","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1742-1241.2011.02812.x","doi":"https://doi.org/10.1111/j.1742-1241.2011.02812.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1742-1241.2011.02812.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2011.02812.x","source":{"id":"https://openalex.org/S22344484","display_name":"International Journal of Clinical Practice","issn_l":"1368-5031","issn":["1368-5031","1742-1241"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Clinical Practice","raw_type":"journal-article"},{"id":"pmid:21977965","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21977965","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of clinical practice","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1111/j.1742-1241.2011.02812.x","doi":"https://doi.org/10.1111/j.1742-1241.2011.02812.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1742-1241.2011.02812.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1742-1241.2011.02812.x","source":{"id":"https://openalex.org/S22344484","display_name":"International Journal of Clinical Practice","issn_l":"1368-5031","issn":["1368-5031","1742-1241"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Clinical Practice","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1596584892.pdf","grobid_xml":"https://content.openalex.org/works/W1596584892.grobid-xml"},"referenced_works_count":31,"referenced_works":["https://openalex.org/W1515933387","https://openalex.org/W1526927233","https://openalex.org/W1532170875","https://openalex.org/W1550111394","https://openalex.org/W1970125713","https://openalex.org/W1982967737","https://openalex.org/W2003786134","https://openalex.org/W2009171980","https://openalex.org/W2013953614","https://openalex.org/W2032392636","https://openalex.org/W2034733131","https://openalex.org/W2045063167","https://openalex.org/W2045321591","https://openalex.org/W2048728983","https://openalex.org/W2056802309","https://openalex.org/W2064410761","https://openalex.org/W2067478339","https://openalex.org/W2073742622","https://openalex.org/W2090920461","https://openalex.org/W2094444824","https://openalex.org/W2094649585","https://openalex.org/W2103058881","https://openalex.org/W2106477777","https://openalex.org/W2114927834","https://openalex.org/W2119691714","https://openalex.org/W2121355767","https://openalex.org/W2126065052","https://openalex.org/W2130850645","https://openalex.org/W2327678893","https://openalex.org/W2334007385","https://openalex.org/W2337454357"],"related_works":["https://openalex.org/W2045321591","https://openalex.org/W2466462025","https://openalex.org/W2343699086","https://openalex.org/W2494769690","https://openalex.org/W603325110","https://openalex.org/W2534221266","https://openalex.org/W1903937137","https://openalex.org/W2276449521","https://openalex.org/W2100987099","https://openalex.org/W1981024765"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Therapeutic":[1],"options":[2],"are":[3],"limited":[4],"for":[5,182,241],"diabetes":[6,30],"patients":[7,26,40,162,200,215,242],"with":[8,27,81,121,139,157,163,184,197,201,243],"renal":[9,34,44,50,164,205,246],"disease.":[10],"This":[11],"report":[12],"presents":[13],"52-week":[14],"results":[15],"from":[16,109],"a":[17],"study":[18,38],"assessing":[19],"the":[20,217],"dipeptidyl":[21],"peptidase-4":[22],"inhibitor":[23],"saxagliptin":[24,57,140,158,198,218],"in":[25,39,69,102,135,150,161,190,199,216],"type":[28],"2":[29],"mellitus":[31],"(T2DM)":[32],"and":[33,87,97,104,219,226,238,245],"impairment.":[35,206,247],"DESIGN:":[36],"Double-blind":[37],"stratified":[41],"by":[42],"baseline":[43,110],"impairment":[45,165],"(moderate,":[46],"severe":[47,174,204],"or":[48,62,93,173,203],"end-stage":[49],"disease":[51],"[ESRD]":[52],"on":[53],"haemodialysis)":[54],"randomised":[55,96],"to":[56,65,111,180],"2.5":[58,231],"mg":[59,232],"once":[60,233],"daily":[61,234],"placebo":[63,142,160,181,220],"added":[64],"other":[66],"antidiabetic":[67],"drugs":[68],"use":[70],"at":[71],"baseline,":[72],"including":[73],"insulin.":[74],"PATIENTS:":[75],"A":[76],"total":[77],"of":[78,118,214],"170":[79],"adults":[80],"glycated":[82],"haemoglobin":[83],"(HbA(1c)":[84],")":[85],"7-11%":[86],"creatinine":[88],"clearance":[89],"<":[90,146],"50":[91],"ml/min":[92],"ESRD":[94,185],"were":[95,114,128,154,194],"treated.":[98],"MEASUREMENTS:":[99],"Absolute":[100],"changes":[101],"HbA(1c)":[103,136,153],"fasting":[105],"plasma":[106],"glucose":[107],"(FPG)":[108],"week":[112],"52":[113],"evaluated":[115],"using":[116],"analysis":[117],"covariance":[119],"(ANCOVA)":[120],"last":[122],"observation":[123],"carried":[124],"forward.":[125],"Repeated-measures":[126],"analyses":[127],"also":[129],"performed.":[130],"RESULTS:":[131],"Adjusted":[132],"mean":[133,152,192],"decrease":[134],"was":[137,208],"greater":[138,156,196],"than":[141,159],"(difference,":[143],"-0.73%,":[144],"p":[145],"0.001":[147],"[ANCOVA]).":[148],"Reductions":[149,189],"adjusted":[151,191],"numerically":[155,195],"rated":[166],"as":[167],"moderate":[168,202],"(-0.94%":[169],"vs.":[170,176,187],"0.19%":[171],"respectively)":[172],"(-0.81%":[175],"-0.49%),":[177],"but":[178],"similar":[179,212],"those":[183],"(-1.13%":[186],"-0.99%).":[188],"FPG":[193],"Saxagliptin":[207,230],"generally":[209],"well":[210],"tolerated;":[211],"proportions":[213],"groups":[221],"reported":[222],"hypoglycaemic":[223],"events":[224],"(28%":[225],"29%":[227],"respectively).":[228],"CONCLUSIONS:":[229],"offers":[235],"sustained":[236],"efficacy":[237],"good":[239],"tolerability":[240],"T2DM":[244]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1596584892","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":22},{"year":2015,"cited_by_count":15},{"year":2014,"cited_by_count":25},{"year":2013,"cited_by_count":19},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
